University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics
September 1, 2022—San Diego, CA—A study led by researchers at the University of Oxford, UK has been published in Lancet Diabetes & Endocrinology, detailing findings which identify putative metabolic pathways that influence fetal growth trajectories and childhood health outcomes. Sapient provided mass spectrometry-based discovery metabolomics with data analysis and chemical interpretation for the study. The research is part… Continue reading University of Oxford Publishes Findings from Its INTERBIO-21st Study Supported by Sapient’s Discovery Metabolomics
Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19
Study infrastructure and biospecimen processing support is being provided by Sapient for the study, which is focused on advancing vital immune response research for COVID-19 and other autoimmune and inflammation-associated diseases. Cedars-Sinai’s press release highlights key study findings now published in JAMA Network Open on COVID-19 infection awareness rates, indicating that 56% of adults in the study… Continue reading Sapient Featured as Collaborator in Cedars-Sinai Study on Immune Responses and COVID-19
Sapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry Analysis
The grant from Bill & Melinda Gates Foundation will support studies to identify biomarkers that can inform novel nutritional, disease-prevention, and disease-treatment interventions July 11, 2022—San Diego, CA—Sapient, a biomarker discovery organization focused on rapid, large-scale biomarker profiling, has been awarded a new grant from the Bill & Melinda Gates Foundation to use its rapid liquid chromatography-mass spectrometry (rLC-MS)… Continue reading Sapient Receives $9.2M Grant for Population-Scale Discovery Mass Spectrometry Analysis
Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022
“Sapient’s proprietary, next-generation rapid LC-MS (rLC-MS) technologies leverage the unique bioanalytical capabilities of the Bruker timsTOF Pro 2 system and enable nontargeted capture and measure of more than 11,000 circulating small molecule biomarkers – including thousands of yet uncharacterized factors – in a human biosample in less than one minute. These technologies are embedded within an integrated discovery pipeline… Continue reading Sapient Featured in Bruker Press Release Announcing timsTOF Innovations at ASMS 2022
Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium
San Diego, CA—Sapient, a biomarker discovery organization transforming drug development through rapid, large-scale biomarker profiling, has joined the Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium, the preeminent group of public-private partners focused on identifying, developing, and qualifying biomarkers to improve drug development and regulatory decision-making. Sapient’s Philip Worboys, PhD, Head of Translational Science,… Continue reading Sapient Joins the Foundation for the National Institutes of Health Biomarkers Consortium
Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report
San Diego, CA—Sapient, a full-service bioanalytical organization transforming drug development through biomarker discovery, has been featured in the Bay Area Lyme Foundation’s 2021 Impact Update report for its collaboration with the Foundation aimed at establishing new diagnostics for persistent Lyme disease (PLD). The report shares insight into the research being conducted by Sapient in leveraging Bay Area… Continue reading Sapient’s Diagnostic Collaboration with Bay Area Lyme Foundation Featured in the Foundation’s Annual Impact Update Report